Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Primary Sclerosing Cholangitis Clinical Trial

Official title:

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04685200
• Other study ID #: 10000130
• Secondary ID: 000130-DK
• Status: Recruiting
• Start date: March 31, 2023
• Est. completion date: October 31, 2024

Study information

• Verified date: June 18, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Alaina Magnani
• Phone: (301) 451-6984
• Email: alaina.magnani[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological causes of primary sclerosing cholangitis. Eligibility: Adults age 18 and older who have primary sclerosing cholangitis. Design: Participants will be screened with a medical history, physical exam, and blood tests. Participants will give blood, saliva, urine, and stool samples. They will have nasal swabs. They will complete surveys. Participants will get an intravenous (IV) catheter. A plastic tube is inserted into an arm vein. Participants will have a colonoscopy. A tube with a video camera at the end is inserted into the rectum. Participants will have an upper endoscopy. A scope with a light and camera at its tip is used to look inside the upper digestive tract. Participants will have a liver biopsy, entering through the chest wall or a neck vein. Blood is drawn from a blood vessel that carries blood to the liver. A liver tissue sample is taken. Participants will have magnetic resonance imaging or spectroscopy. They will get a contrast agent through an IV. Participants may have an optional bone marrow aspiration. A large needle is inserted into the hip to withdraw marrow. Participants will have a liver ultrasound. Participants will complete a 3-day food diary. They will have a nutrition assessment. Participants may give contact details for people who live with them, to also take part in this study. Participation will last for 12 months....

Description:

Study Description: We hypothesize that primary sclerosing cholangitis (PSC) develops as a consequence of a genetically driven aberrant immune response to commensal or pathogenic bacteria, and that unique genetic-immunemicrobial associations may underlie development of distinct disease patterns. We intend to conduct a thorough radiologic, endoscopic, histologic and microbiological investigation of patients with PSC in order to determine potential associations. Objectives: Primary Objective: The ultimate goal of this study is to generate understanding of how factors driving pathogenesis in PSC interact by capturing and integrating collated datasets from across relevant biologic systems and interpreting those in the context of phenotypic presentation in one exceptionally well-characterized set of patients. Secondary Objectives: 1. To collect comprehensive data on distinct patterns of disease expression, through single cell sequencing and microRNA and transcriptome profiling. 2. To conduct extensive phenotypic characterization of cellular and humoral immune responses as well as microbiome signatures at multiple anatomic sites. 3. To evaluate metabolic signatures or biomarkers for PSC diagnosis and prognostication. 4. To generate a humanized mouse model of each subject s disease by obtaining bone marrow aspirate. Endpoints: Primary Endpoint: 1. Identification of immune signatures at multiple levels and from different anatomical sites and tissues 2. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species. 3. Identification of metabolomic signatures from different anatomical sites and tissues as well as identification of different biomarkers correlating with disease progression. 4. MicroRNA profiling of portal and systemic blood.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 143
• Est. completion date: October 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

• PSC SUBJECTS:

INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study

2. Male or nonpregnant female, greater than or equal to 18 years of age

3. Evidence of PSC established by biochemical testing and either MRCP or ERCP. Participant must have evidence of large duct disease on imaging.

4. Agreement to adhere to Lifestyle Considerations throughout study duration. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation

in this study:

1. Pregnant or lactating women or females of child-bearing age not taking measures to prevent pregnancy during the period of study.

2. History of clinical, serologic, or histopathologic evidence supporting etiologies of chronic liver disease other than PSC

3. History of liver transplantation

4. Diagnosis consistent with secondary sclerosing cholangitis (cholelithiasis, bile duct strictures secondary to ischemia, HIV cholangiopathy, etc.).

5. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy, etc.).

6. History of liver or bile duct lesions concerning for malignancy.

7. Ca-19-9 >130 U/microL

8. Alpha-fetoprotein level greater than 200 ng/microL.

9. Patients with active bacterial, viral, or fungal, systemic or localized infection.

10. Unwillingness to refrain from ingesting probiotics during study.

11. History of systemic disease not related to PSC that is poorly controlled or associated with declining functional status. Examples include but are not limited to: poorly controlled diabetes mellitus, chronic renal failure with eGFR is <60 microl/min/1.73m^2, chronic symptomatic heart failure or severe COPD.

12. Patients with history of any gastrointestinal malignancy in the last 3 years prior to enrollment will be excluded. Patients with history of any malignancy in the last 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded.

13. History of portal vein thrombosis

14. Patients with severe allergic reactions to iodine or other contrast, which cannot be controlled by premedication with antihistamines or steroids.

15. History of gastric and/or proximal small bowel surgery including bariatric surgery such as Roux-en-Y gastric bypass

16. Contraindication to monitored anesthesia care and/or medications that are commonly used for conscious sedation during GI Endoscopy

17. Use of anti-coagulant and anti-platelet agents excluding aspirin and NSAIDs

18. Contraindications to completing MRCP or MRI

19. Absolute neutrophil count below 1000/mm^3

20. Hemoglobin level below 10.0 g/dl

21. Platelet count lower than 50,000/mm^3.

22. INR greater than or equal to 1.5, PTT greater thna or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis.

23. Inability to provide informed consent CONTROLS: INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

1. Male or female greater than or equal to 18 years of age

2. Any individual who is either a parent, sibling or child of a PSC patient enrolled to the study, or an unrelated person who has been living with the patient for at least 3 consecutive months before study enrollment EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation

in this study:

1. History suggestive of PSC

2. History of chronic liver disease (except for steatosis)

3. Patients with history of any malignancy in the last 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded.

4. History of Inflammatory Bowel Disease

5. Antibiotic use within the last 6 weeks

6. Pregnancy

7. Inability to provide informed consent

Related Conditions & MeSH terms

• Cholangitis
• Cholangitis, Sclerosing
• Primary Sclerosing Cholangitis

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The ultimate goal of this study is to generate understanding of how factors driving pathogenesis in PSC interact by capturing and integrating collated datasets from across relevant biologic systems and interpreting those in the context of phenot...	1. Identification of immune signatures at multiple levels and from different anatomical sites and tissues 2. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species. 3. Identification of metabolomic signatures from different anatomical sites and tissues as well as identification of different biomarkers correlating with disease progression. 4. MicroRNA profiling of portal and systemic blood.	End of Study
Secondary	To collect comprehensive data on distinct patterns of disease expression, through single cell sequencing and microRNA and transcriptome profiling.	Single cell sequencing, microRNA and transcriptome profiling	End of Study
Secondary	To conduct extensive phenotypic characterization of cellular and humoral immune responses as well as microbiome signatures at multiple anatomic sites	Immune phenotyping, immune repertoire sequencing and cytokine profiling techniques, as well as next generation sequencing of microbiota in saliva, stool, blood, bile, small intestine, colon and liver tissue	End of Study
Secondary	To evaluate metabolic signatures or biomarkers for PSC diagnosis and prognostication	High throughput metabolomics screening of portal and systemic blood, liver tissue and bile in search of bile acids and other target metabolites	End of Study
Secondary	To generate a humanized mouse model of each subject s disease by obtaining bone marrow aspirate	The study of immune phenotype and function in a host (in this case the mouse) na(SqrRoot) ve to immunosuppressive therapy	End of Study

External Links

•   NIH Clinical Center Detailed Web Page